The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pilot study evaluating the addition of cemiplimab in BRAF-mutant anaplastic thyroid cancer after progression on dabrafenib and trametinib.
 
Eric Sherman
Consulting or Advisory Role - AffyImmune Therapeutics; Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - Fore Biotherapeutics (Inst); HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst)
 
Loren Michel
Consulting or Advisory Role - KisoJi Biotechnology
Research Funding - Exelixis
 
Anuja Kriplani
No Relationships to Disclose
 
Winston Wong
Research Funding - BioAtla; Hookipa Biotech
 
Sofia Haque
Honoraria - Advance Medical
Consulting or Advisory Role - Advance Medical
 
Ranieri Yllanes
No Relationships to Disclose
 
Jeffrey Knauf
Patents, Royalties, Other Intellectual Property - CCF-41469.102, Title: Fusion Neoantigens for use in Cancer Vaccines, Antibody therapy, and cell applications.; MSK Ref. pending: Targeting the adaptive responses of BRAF or RAS-mutant thyroid cancers to RAF/MEK inhibitors with bispecific antibodies to TSHR and/or HER2. Application number: pending.; MSK Ref. SK 2014-024-03 Title: Treatment of H-RAS-Driven Tumors. Application Number: 15/305,788. Date Filed: October 21, 2016.; MSK Ref. SK2016-008-01 Title: Thyroid Differentiation Classifier for Patient Stratification in Thyroid Cancer. Application Number: 62/342,164.
 
James Fagin
Patents, Royalties, Other Intellectual Property - ventors Title of Invention Patent Number James Alexander Fagin 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl) pyrimidin-2-ylamino) ph
 
Alan Ho
Consulting or Advisory Role - AffyImmune Therapeutics; Coherus Biosciences; Eisai; Exelixis; Hookipa Biotech; InhibRx; Kura Oncology; Lepu Biopharma; Nested Therapeutics; Rgenta; Takeda
Speakers' Bureau - Mt. Sinai; Physicans' Education Resource
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Daiichi; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Hookipa Biotech; Kura Oncology; Merck; Novartis; OncC4; Poseida; Remix Therapeutics; Rgenta; TILT Biotherapeutics; Verastem
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN